Your Health: Popular weight-loss drugs are meant to be lifelong treatments for a disease, not lifestyle fixes, columnist Sumathi Reddy writes. https://t.co/yGcWF7TfHE ...

As the body positivity era gives way to a “thin is in” moment, telehealth companies are aggressively marketing Ozempic and other weight-loss drugs not as medicines for obesity or diabetes, but as cosmetic elixirs for anyone to lose a few pounds https://t.co/vmafcGJ90O ...

Industry Trend - Weight-loss drugs like Ozempic are seen as a potential solution to obesity [1] Social Impact - Fat activists are posing a challenge to the use of weight-loss drugs [1]

Industry Trend - Weight-loss drugs like Ozempic are seen as a potential solution to obesity [1] Social Impact - Fat activists are posing a challenge to the use of weight-loss drugs [1]

Ozempic and other weight-loss drugs may be a promising solution to the growing problem of obesity, but they’ve got a surprising foe: fat activists. https://t.co/wdC7XHm73J ...

Industry Trend - Weight-loss drugs like Ozempic are seen as a potential solution to the increasing obesity issue [1] Social Impact - Fat activists are posing a challenge to the widespread acceptance of weight-loss drugs [1]

Industry Trend - Weight-loss drugs like Ozempic are seen as a potential solution to obesity [1] Potential Challenges - Fat activists are posing a challenge to the widespread acceptance of weight-loss drugs [1]

Industry Perspective - Pharmaceuticals alone cannot solve the weight-loss crisis affecting over 1 billion people worldwide [1]

Legal & Regulatory Actions - Novo Nordisk is expanding legal action to protect patents from unsafe, non-FDA approved semaglutide [1] - Novo Nordisk has filed 132 lawsuits in federal court regarding compounded GLP-1s [7] - The President sent letters to 17 large drug makers asking them to lower drug prices in the US [11] Company Performance & Strategy - Novo Nordisk significantly lowered its full-year guidance partly due to compounded GLP-1s [6] - Offboarding of consumers to branded drugs like Ozempic and Wegovy is occurring [4] - Pfizer beat earnings expectations due to strength across most of its drugs and vaccines [9] - Pfizer is planning to cut approximately $8 billion in costs [10] - Pfizer raised its full-year adjusted EPS due to cost-cutting and a lower tax rate [10] Market Dynamics & Competition - Compounding has been primarily focused on semaglutide, the main ingredient in Ozempic and Wegovy [8] - Analysts are not expecting the compounding issue to be as significant for Eli Lilly as it is for Novo Nordisk [8] - Discussions between drug companies and the administration regarding drug prices are ongoing [12]